Today, our science has broad applications in the field of infectious diseases and oncology
VAC-3S VAC-3S has demonstrated its ability to produce anti-3S antibodies in a clinical meaningful way in 52% of patients treated in phase 1 and phase 2 clinical studies. Vaccine safety is confirmed in the 131 patients treated in these studies.
VAC-02 These results open therapeutics application opportunities beyond vaccinology and HIV in the field of infectious diseases.
P44-L P44-L is curently in validation in various disease models of oncology for CAR-T and CAR-NK development.
4 avenue de l’Opéra, 75001 Paris